

1 **Title: Motor Protein MYO1C is Critical for Photoreceptor Opsin Trafficking and**
2 **Visual Function**

3
4 **Authors:** Ashish K. Solanki^{1#}, Stephen Walterhouse^{1#}, René Martin², Elisabeth Obert³,
5 Ehtesham Arif¹, Bushra Rahman¹, Barbel Rohrer^{3,4}, Joshua Lipschutz^{1,4}, Rupak D.
6 Mukherjee⁵, Russell A. Norris⁶, Jeffery Sundstrom⁷, Hans-Joachim Knölker², Shahid
7 Husain^{3*}, Manas R. Biswal^{8*}, Deepak Nihalani^{9*} and Glenn P. Lobo^{1,3*}

8
9 **Affiliations:** ¹Department of Medicine, Medical University of South Carolina, Charleston,
10 SC 29425, USA. ²Faculty of Chemistry, Technische Universität Dresden, Bergstraße 66,
11 01069 Dresden, Germany. ³Department of Ophthalmology, Medical University of South
12 Carolina, Charleston, SC 29425, USA. ⁴Ralph H. Johnson VA Medical Center, Division of
13 Research, Charleston, SC 29420, USA. ⁵Department of Surgery, College of Medicine,
14 Medical University of South Carolina, Charleston, SC 29425, USA. ⁶Department of
15 Regenerative Medicine and Cell Biology, Children's Research Institute, Medical
16 University of South Carolina, Charleston, SC 29425, USA. ⁷Penn State Eye Center, 200
17 Campus Dr., Suite 800, Hershey, PA 17033. USA. ⁸Department of Pharmaceutical
18 Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612,
19 USA. ⁹National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
20 National Institutes of Health, Bldg 2DEM, Room 6085, 6707 Democracy Blvd., Bethesda,
21 MD 20817, USA.

22
23 # Equal contribution

24
25 *** Corresponding Authors**

26
27 ***Glenn P. Lobo, Ph.D.**
28 Assistant Professor
29 Department of Medicine
30 Medical University of South Carolina
31 70 President Road
32 Drug Discovery Building DDB513
33 Charleston, SC 29425, USA.
34 Office: 843-876-2371
35 Fax: 843-792-8399
36 E-mail: lobo@musc.edu

37
38 ***Deepak Nihalani, Ph.D.**
39 Program Director, KUH
40 Bldg 2DEM, Room 6085
41 6707 Democracy Blvd
42 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
43 National Institutes of Health
44 BETHESDA, MD 20817, USA.
45 Office: 301-555-5555
46 E-mail: nihalanideepak@hotmail.com

47 ***Manas R. Biswal, Ph.D.**
48 Assistant Professor
49 Department of Pharmaceutical Sciences
50 Taneja College of Pharmacy, University of South Florida
51 12901 Bruce B. Downs Blvd, MDC-30
52 Tampa, FL 33612, USA.
53 Office: 813-974-8333
54 E-mail: biswal@usf.edu

55
56 ***Shahid Husain, Ph.D.**
57 Professor
58 College of Medicine
59 Department of Ophthalmology
60 Medical University of South Carolina
61 Charleston, SC 29425, USA.
62 Office: 843-792-2792
63 E-mail: husain@musc.edu

64
65
66 **Keywords:** Motor protein, Myosin, MYO1C, Rhodopsin, Photoreceptor, Outer Segments,
67 Trafficking, Visual function.
68

69 **Abstract**

70 Unconventional myosins linked to deafness are also proposed to play a role in retinal cell
71 physiology. **However, their direct role in photoreceptor function remains unclear.** We
72 demonstrate that systemic loss of the unconventional myosin MYO1C in mice specifically
73 affected opsin trafficking, leading to loss of visual function. Electroretinogram analysis of
74 *Myo1c* knockout (*Myo1c*-KO) mice showed a progressive loss of photoreceptor function.
75 Immunohistochemistry and binding assays demonstrated MYO1C localization to
76 photoreceptor inner and outer segments (OS) and identified a direct interaction of
77 rhodopsin with the MYO1C cargo domain. In *Myo1c*-KO retinas, rhodopsin mislocalized
78 to rod inner segments (IS) and cell bodies, while cone opsins in OS showed punctate
79 staining. In aged mice, the histological and ultrastructural examination **of the phenotype**
80 **of *Myo1c*-KO retinas** showed progressively shorter photoreceptor OS. These results
81 demonstrate that MYO1C is critical for opsin trafficking to the photoreceptor OS and for
82 normal visual function.

83

84

85

86

87

88

89

90 **Introduction**

91 Protein trafficking within the photoreceptors must occur efficiently and at high fidelity for
92 photoreception, photoreceptor structural maintenance, and overall retinal cell
93 homeostasis. Additionally, it is well-known that proper opsin trafficking is tightly coupled
94 to photoreceptor cell survival and function [1-9]. However, the cellular events that
95 participate in retinal injuries due to improper signaling and protein trafficking to the
96 photoreceptor outer segments (OS), are not yet fully understood. While many proteins
97 are known to play an essential role in retinal cell development and function, the
98 involvement of motor proteins in eye biology is less understood. Identification of genetic
99 mutations in the *Myo7a* gene associated with retinal degeneration in Usher syndrome
100 suggests that unconventional myosins play a critical role in retinal pigmented epithelium
101 (RPE) and photoreceptor cell function [10, 11]. Unconventional myosins are motor
102 proteins that are proposed to transport membranous organelles along the actin filaments
103 in an adenosine triphosphate (ATP)-dependent manner, and additional roles are currently
104 being discovered [12-14]. The loss of *Myo7a* primarily affects RPE and OS phagocytosis
105 leading to retinal cell degeneration. However, it is believed that other yet unidentified class
106 I myosins may participate more directly in photoreceptor cell function. Here we present
107 compelling evidence for another unconventional actin-binding motor protein, MYO1C,
108 with its primary localization to photoreceptors that plays an important role in retinal cell
109 structure and function via opsin trafficking to the photoreceptor OS.

110 **Rhodopsin and cone pigments in photoreceptor OS mediate scotopic and photopic**
111 **vision, respectively. The visual pigment rhodopsin is a prototypical G-protein coupled**
112 **receptor (GPCR) expressed by retinal rods for photon absorption. Light sensitivity is**

113 conferred by 11-*cis* retinaldehyde, a chromophore that is covalently linked to the K296
114 residue of the opsin protein [15-19] Photon absorption causes a *cis* to *trans*
115 conformational shift in the retinaldehyde, leading to structural changes in the opsin protein
116 moiety [6]. This initiates a GPCR signaling pathway/phototransduction cascade, signaling
117 the presence of light. Each photoreceptor cell contains an OS housing the
118 phototransduction machinery, an inner segment (IS) where proteins are biosynthesized,
119 and a synaptic terminal for signal transmission. One of the fundamental steps in vision is
120 the proper assembly of signal-transducing membranes, including the transport and
121 sorting of protein components. A major cause of neurodegenerative and other inherited
122 retinal disorders is the improper localization of proteins. Mislocalization of the dim-light
123 photoreceptor protein rhodopsin is a phenotype observed in many forms of blinding
124 diseases, including retinitis pigmentosa (RP). The proteins that participate in
125 phototransduction (including rhodopsin, transducin, phosphodiesterase [PDE6], or the
126 cyclic nucleotide-gated channels [CNG]) are synthesized in the IS and must be
127 transported through the connecting cilium to the OS. These proteins are either
128 transmembrane or peripherally associated membrane, which are attached to the
129 membrane surface [1-9]. How the transmembrane proteins (e.g., rhodopsin and CNG)
130 and peripherally associated proteins (e.g., transducin and PDE6) traffic through the IS to
131 incorporate eventually in the nascent disc membrane or the photoreceptor outer
132 membrane is not fully understood and constitutes an area of intense research, as
133 improper trafficking of these protein causes retinal cell degeneration and can lead to
134 blindness [1-9].

135 Genetic mutations in myosins that lead to hearing loss have also been associated
136 with retinal degeneration. Some of the essential genes involved in either or both of these
137 functions belong to a family of unconventional motor proteins and include MYO3A [20],
138 MYO7A, MYO6, MYO15 [20-22], and MYO5. Recently, it was reported that another
139 unconventional myosin, MYO1C, where mutations affected its nucleotide-binding pocket
140 and calcium binding ability and these were associated with deafness [23]. Importantly,
141 MYO1C was identified in proteomic analysis of the retina and vitreous fluid as part of a
142 protein hub involved in oxidative stress [23-25]. MYO1C is an actin-binding motor protein
143 that is widely expressed in multiple cell types. It participates in a variety of cellular
144 functions, including protein trafficking and translocation [12, 26-28]. As MYO1C has low
145 tissue specificity based on mRNA and protein expression, it remains unclear which cell
146 type is most dependent on MYO1C trafficking function and is affected by the loss of
147 MYO1C.

148 In this study, we systematically analyzed the function of the unconventional motor
149 protein MYO1C in protein trafficking in photoreceptors. We found that a global genetic
150 deletion of *Myo1c* resulted in a retinal phenotype only, which manifested as a progressive
151 mistrafficking of opsins to the OS. Using retinal lysate from wild-type (WT) mice in co-
152 immunoprecipitation assays, we showed that MYO1C and rhodopsin directly interact,
153 indicating that opsin was a cargo for MYO1C. Loss of MYO1C promoted a progressive
154 shortening of OSs that was concomitant with a reduction in photoreceptor function,
155 suggesting that MYO1C is critical for maintenance of photoreceptor cell structure and for
156 visual function. Our findings have significant clinical implications for degenerative rod and
157 cone diseases, as mutations in MYO1C or its interacting partners are predicted to affect

158 retinal health and visual function by altering opsin trafficking to the photoreceptor OS, a
159 fundamental step for maintaining visual function in humans.

160

161 **Results**

162 **Construction and Validation of *Myo1c* Null Mice:** We previously generated *Myo1c*
163 floxed mice using the standard knockout strategy [29] (**Fig. S1a**). Systemic deletion of
164 *Myo1c* was achieved by crossing *Myo1c* floxed (*Myo1c^{fl/fl}*) mice with Actin Cre+
165 (ActCre+; JAX labs) mice to generate *Myo1c^{fl/fl}-ActCre+/-* knockout mice (referred to as
166 *Myo1c*-KO mice in this manuscript). Western blotting of protein lysates from various
167 tissues including kidney, heart, and liver of *Myo1c*-KO mice showed complete loss of
168 MYO1C, thus confirming the systemic deletion of *Myo1c* (**Fig. S1b**). Additionally,
169 immunofluorescence expression analysis of these tissues further confirmed loss of
170 MYO1C protein in *Myo1c*-KO mice (**Figs. S2a-c**).

171

172 **Genetic Deletion of *Myo1c* induced Visual Impairment in Mice:** Immunofluorescence
173 analysis showed that MYO1C was enriched in the rod photoreceptor outer (OS) and inner
174 segments (IS) (**Fig. 1a**), and also in cone photoreceptor OS of wild-type (WT) mice (**Fig.**
175 **1b**), but absent in photoreceptors of *Myo1c*-KO animals (**Figs. 1a and 1c**). Western blot
176 analysis further confirmed that MYO1C protein was absent in the retinas of *Myo1c*-KO
177 mice (**Fig. 1d**). Since mutations or deletion of the motor protein MYO7A were associated
178 with retinal degeneration in Usher syndrome and its animal model, it prompted us to
179 investigate the effect of *Myo1c* in retinal function. Using electroretinograms (ERGs) [30,
180 31], we tested photoreceptor cell function of *Myo1c*-KO and WT mice (*n*=8 mice per

181 **genotype and age-group; 50:50 ratio of male and female) under dark-adapted scotopic**
182 **conditions.** In contrast to WT animals, we observed reduced ERGs for *Myo1c*-KO mice
183 at different ages. Two month old *Myo1c*-KO mice showed a significant reduction in the **a-**
184 wave amplitudes, but not in **b**-wave amplitudes ($p < 0.0068$ and $p < 0.098$, respectively)
185 (**Figs. 2a** and **2c**). Strikingly, ERG analysis of adult six months old *Myo1c*-KO mice
186 showed severe loss of retinal function, in which a significant reduction in both **a-** and **b-**
187 waves was observed (38-45% lower than WT animals (** $p < 0.005$; **Figs. 2b** and **2d**).

188

189 **Trafficking of Rod and Cone Visual Pigments in *Myo1c*-KO Mice:** Since the
190 phototransduction protein rhodopsin constitutes 85-90% of photoreceptor OS protein
191 content [32], and as the ERG responses were impaired in *Myo1c*-KO mice, we
192 hypothesized that the loss of MYO1C might have affected opsin trafficking to the
193 photoreceptor OS. To test this hypothesis, we analyzed retinal sections from WT and
194 *Myo1c*-KO mice (at 2 and 6 months of age; 5-7 retinal sections per eye from $n=8$ mice
195 per genotype and age-group; 50:50 ratio of male and female), probing for rhodopsin, two
196 types of cone opsins, medium wavelength R/G opsin (M-opsin) and short wavelength S-
197 opsin, rod-specific phosphodiesterase 6b (Pde6b), rod-specific CNGA1, rod arrestin
198 (ARR1), rod transducin (G-protein), and the general cone marker, PNA lectin. In WT mice
199 at 2 and 6 months of age, rhodopsin localized exclusively to the rod OS (**Fig. 3a**). While
200 majority of rhodopsin trafficked to the OS in two month old *Myo1c*-KO mouse retinas,
201 some mislocalization to the base of the rod IS and the cell bodies in the outer nuclear
202 layer (ONL) was noted (**Fig. 3a**; white arrows; rhodopsin levels within individual retinal
203 layers were quantified and shown in **Figs. S3a-c**). This suggested incomplete opsin

204 transport/trafficking to photoreceptor OS in the absence of MYO1C. An even more severe
205 mislocalization of rhodopsin to the rod IS and within the ONL was observed in the 6-month
206 old *Myo1c*-KO mice, suggesting a progressive retinal phenotype in the absence of
207 MYO1C (**Fig. 3a**; rhodopsin expression within individual retinal layers were quantified and
208 shown in **Figs. S3d-e**). Staining for the two cone opsins showed that the cone OS were
209 shorter and mis-shaped by two months and this abnormality increased by six months of
210 age (**Figs. 3b** and **3c**). Retinas stained for PNA lectin, showed progressively shorter and
211 mis-shaped cone OS, indicating that cone OS structure was compromised in the absence
212 of MYO1C as these mice aged (**Fig. 3d**). Cone visual arrestin in WT mice retina typically
213 outlines the entire cell, OS, IS, cell body, axon, and cone pedicle. Staining for cone
214 arrestin in *Myo1c*-KO animals (2 month of age) confirmed the short and mis-shaped
215 appearance of the cone OS compared to WT retinas at similar ages (**Fig. 4a**, white
216 arrows). In contrast, staining for Pde6b, a lipidated rod specific protein that trafficks to the
217 OS independently of rhodopsin [33], showed normal trafficking and localization to the rod
218 OS in both WT and *Myo1c*-KO retinas, at 2 month of age (**Fig. 4b**).

219 The CNG channels are also important mediators in the photoreceptor transduction
220 pathways, and they require proper localization to the OS for normal photoreceptor cell
221 function [5]. Additionally, the absence of CNGA1 or CNGB1 in mice led to decreased ERG
222 responses and progressive rod and cone photoreceptor cell death [5]. Therefore, to rule
223 out alternate mechanisms for the observed functional phenotypes in *Myo1c*-KO retinas,
224 the retinas of WT and *Myo1c*-KO mice (3-4 months of age; 5-7 retinal sections per eye
225 from $n=8$ mice per genotype; 50:50 ratio of male and female) were stained with the
226 CNGA1 antibody. This analysis showed that even in the absence of MYO1C, both young

227 and adult mice retinas showed no defects in the trafficking of CNGA1 protein to OS (**Fig.**
228 **4c**; CNGA1 protein distribution in photoreceptor layer quantified and shown in **Fig. 4f**).

229 The soluble proteins arrestin and transducin exhibit light-dependent trafficking,
230 where in response to light, arrestin migrates to rod OS and transducin translocates to rod
231 IS [34]. To test whether the loss of MYO1C affected rod arrestin (ARR1) and rod G-protein
232 (transducin) localization, we performed IHC staining for these proteins in retinas of light
233 adapted WT and *Myo1c*-KO mice (3-4 months of age; 5-7 retinal sections per eye from
234 $n=8$ mice per genotype; 50:50 ratio of male and female). These analyses showed that in
235 the presence of light, genetic loss of MYO1C had no negative effect on the trafficking of
236 rod arrestin to the OS and G-protein to the IS and cell bodies in retinas of *Myo1c*-KO mice
237 (**Figs. 4d** and **4e**; rod ARR1 and transducin protein distribution in photoreceptor layer
238 quantified and shown in **Fig. 4f**). Using total protein lysates from retinas of WT and
239 *Myo1c*-KO mice (3-4 months of age; four pooled retinas from $n=2$ mice per genotype) we
240 analyzed protein expression of key retinal proteins in specific retinal cells: CRABP1
241 (expressed in Müller cells), GNAT1 (expressed in photoreceptors), and PKC α (expressed
242 in retinal bipolar cells). These analyses showed no significant differences in the
243 expression of these genes in the inner or outer-retinal layers of *Myo1c*-KO mice when
244 compared to WT mice, at 3-4 months of age (**Fig. 4g**). Although MYO1C could not be
245 detected by immunohistochemical analysis in mouse RPE, functional MYO1C and *Myo1C*
246 mRNA were reported in human RPE cells [35] and mouse RPE [36], respectively. Since
247 elimination of the motor protein *Myo7a* in mouse leads to alterations in protein localization
248 in the RPE (RPE65) [37], we stained retinas of young and adult WT and *Myo1c*-KO mice
249 (5-7 retinal sections per eye from $n=8$ mice per genotype) with an anti-STRA6 antibody,

250 another RPE-specific protein. This analysis showed that STRA6 expression and
251 localization in the RPE was not affected in the absence of MYO1C (**Fig. S4**). Since
252 MYO1C is known primarily as a motor protein with a protein trafficking function [14, 23],
253 we next tested the hypothesis that its absence in photoreceptors of *Myo1c*-KO animals
254 may contribute specifically to the loss of opsin trafficking to the photoreceptor OS.

255

256 **Native Cre⁺ mice showed no retinal phenotypes:** To rule out any Cre⁺-mediated
257 effects on retinal phenotypes observed in the *Myo1c*-KO;Cre⁺ animals, the eyes from
258 native Cre⁺ mice (3-4 months old; *n*=3 animals) were harvested and subjected to similar
259 histological and immunofluorescence analysis. As compared to age-matched WT mice
260 retinas (*n*=3 animals), the retinas of Cre⁺ mice showed no retinal pathology or
261 mislocalization of opsins (**Figs. S5a vs. S5b**). These analyses support the view that
262 genetic loss of MYO1C affects key components of phototransduction specifically, and this
263 is further manifested in defects in visual function.

264

265 ***Myo1c*-KO Mice demonstrated Photoreceptor OS Loss:** To evaluate further if opsin
266 mistrafficking is associated with structural changes to the retina, histological and
267 transmission electron microscopy (TEM) analyses of retinal sections of young and adult
268 WT and *Myo1c*-KO mice were performed. In histological sections of retinas (5-7 retinal
269 sections per eye from *n*=8 mice per genotype and age), progressive shortening of rod
270 photoreceptor OS was observed. The OS of adult *Myo1c*-KO mice at 6 months of age
271 were shorter than the OS of *Myo1c*-KO mice at 2 months of age, which in turn were
272 shorter than those in WT mice at similar ages (**Figs. 5a and 5b; OS lengths quantified**

273 from H&E sections and represented using spider-plots in **Figs. 5c and 5d**; $**p<0.05$). In
274 comparison to WT mice, the photoreceptors in *Myo1c*-KO mice were less organized,
275 especially in the 6-month old mice (**Fig. 5b**), suggesting that loss of MYO1C may
276 progressively affect photoreceptor homeostasis. The retina **outer nuclear layer (ONL)**
277 **thickness between genotypes at both ages revealed no significant reduction in nuclear**
278 **layers in *Myo1c*-KO animals compared to WT mice (ONL thickness quantified from H&E**
279 **stained sections and represented using spider-plots in **Figs. 5e and 5f**).**

280

281 **Ultrastructural TEM analysis showed shorter photoreceptor OS in *Myo1c*-KO mice:**

282 To evaluate the structure of rod photoreceptors, ultrastructural analysis using TEM was
283 performed ($n=6$ retinal sections per eye from $n=8$ mice per genotype and age). While the
284 rod photoreceptor OS in the WT mice showed normal elongated morphology, they
285 appeared slightly shorter in *Myo1c*-KO mice at two months of age ($*p<0.05$; **Fig. 6a**; rod
286 OS lengths quantified in **Fig. 6e**). Specifically, comparing *Myo1c*-KO with WT mouse rod
287 OS lengths at six months of age demonstrated that OS segment lengths in *Myo1c* retinas
288 were significantly (**36-45%**) shorter than those of WT mice ($**p<0.005$; **Fig. 6b**; rod OS
289 lengths quantified in **Fig. 6e**). Ultrastructurally, the cone OS in the *Myo1c*-KO mouse
290 retina were shorter and had lost their typical cone shape (**Fig. 6c vs. 6d**; cone OS lengths
291 quantified in **Fig. 6f**), confirming the **mis-shaped cone OS phenotype identified by**
292 **immunohistochemistry (**Figs. 3b-d**).** These results suggest that the lack of MYO1C
293 resulted in progressively severe opsin mislocalization (**Figs. 3a-d**), and shorter
294 photoreceptor OS (**Figs. 5 and 6**), thus supporting the observed decrease in visual
295 function by ERG (**Fig. 2**).

296 **Molecular inhibition of MYO1C motor function by PCIP in mice affected Opsin**
297 **trafficking:** To confirm a direct role for the motor protein MYO1C in opsin trafficking and
298 that the loss of MYO1C contributed specifically to opsin mistrafficking in photoreceptors,
299 we molecularly inhibited MYO1C in vivo using PCIP (pentachloropseudilin) which
300 specifically can inhibit the motor activity of MYO1C [38-41]. To achieve this, a single dose
301 of PCIP in DMSO (5mg/kg) was injected retro-orbitally into the right eye of WT animals
302 ($n=2$). A control set of WT animals ($n=2$) received vehicle control/diluent (DMSO) under
303 similar conditions. Post 7-8 hours injection, mice were euthanized and both eyes were
304 harvested and fixed in PBS buffered 4% paraformaldehyde. Retinal cell phenotype and
305 opsin trafficking in PCIP and DMSO injected animals were assessed using retinal
306 histology and immunofluorescence to assess rod and cone opsin trafficking to the OS. In
307 photoreceptors of mice eyes injected with the vehicle control DMSO, rhodopsin localized
308 exclusively to the rod OS (**Fig. 7a**). In contrast, the mice injected with PCIP showed
309 mislocalization of rhodopsin to the base of the rod IS and the cell bodies in the ONL,
310 demonstrating incomplete opsin trafficking to the photoreceptor OS in PCIP injected mice
311 retinas (**Fig. 7a**; white arrows). Observation of retinal phenotypes in the left eyes of these
312 animals indicated that injected PCIP was systemically distributed (**Fig. 7a**). Staining for
313 the R/G cone opsins (M-opsins) in retinas of these animals showed that in comparison to
314 the control mice the cone OS of PCIP injected mice were shorter and lost their typical
315 elongated cone morphology (**Fig. 7b**). The histological analysis of retinal sections showed
316 significant shortening of photoreceptor OS in mice retinas injected with PCIP (**Fig. 7c**).
317 Additionally, the quantification of retinal ONL thickness in PCIP injected mice showed that
318 ONL was slightly thinner in comparison to control mice (ONL thickness quantified from

319 H&E sections and represented using spider-plots in **Fig. 7d**). OS lengths were
320 significantly shorter in PCIP injected mice (* $p < 0.05$; **Fig. 7c**; quantified from H&E sections
321 and represented using spider-plots in **Fig. 7e**). These retinal phenotypes were similar to
322 those observed in the retinas of *Myo1c*-KO mice at two and six months (**Figs. 3, 5a, and**
323 **6**). Collectively, these results indicate that MYO1C is critical for opsin trafficking to
324 photoreceptor OS and its loss specifically affects opsin trafficking, photoreceptor cell
325 homeostasis, and visual function.

326

327 **MYO1C Directly Interacted with Rhodopsin:** Since the loss of MYO1C resulted in
328 retinal function defects with significant alterations in the localization of opsins, we next
329 evaluated whether MYO1C exerted this effect through a physical interaction with
330 rhodopsin. Immunoprecipitation analysis using WT and *Myo1c*-KO mice retinas ($n=6$
331 retinas pooled from $n=3$ animals per genotype, respectively) **demonstrated that rhodopsin**
332 **was pulled down using MYO1C antibody, and this interaction was confirmed in a**
333 **reciprocal fashion (Fig. 8a; Co-IP flow-chart schematic shown in Fig. S6)**. Using a
334 baculovirus-produced purified recombinant mouse MYO1C protein in an overlay assay,
335 we demonstrated that MYO1C directly interacted with rhodopsin, where opsin was
336 immunoprecipitated both from mouse retinal lysate or HEK293 cells transfected with
337 pCDNA3 Rod Opsin in order to overexpress Rhodopsin (**schematic representation in Fig.**
338 **S6**). Immunoprecipitated rhodopsin was subjected to western blotting and probed with
339 purified recombinant full-length MYO1C (**MYO1C FL; Fig. 8b and schematic in Fig. S6**)
340 or GFP-MYO1C-790-1028 (**MYO1C tail domain, also known as the cargo domain; Fig.**
341 **8c and Fig. S6**) [13]. Post-incubation, the interaction of immobilized rhodopsin to Myo1c

342 was probed using a MYO1C antibody. The immunoblot analysis of the over-layered
343 MYO1C showed significant binding of both MYO1C proteins, full-length and the tail
344 domain, at the rhodopsin band, indicating a direct interaction between the two proteins
345 (**Figs. 8b and 8c**). Interestingly, the interaction of MYO1C was noted with various
346 multimers of rhodopsin, which further indicated that opsin is a cargo for MYO1C (arrows
347 in **Figs. 8b and 8c**).

348

349 **Genetic Deletion of *Myo1c* did not affect Systemic Organs in Mice:** Finally, to
350 determine if the global deletion of *Myo1c* affected other organs, we harvested major
351 systemic organs, including liver, heart, and kidney of 2 month old *Myo1c*-KO and WT
352 mice ($n=4$ per genotype), and performed histological analyses. Notably, *Myo1c*-KO mice
353 developed and reproduced normally with no observable histological differences between
354 the control and *Myo1c*-KO genotypes (**Figs. S7a-c**). To further confirm that there were
355 no functional defects in these systemic organs, we performed ECHOCardiogram (heart
356 function), quantified protein/albumin levels in urine (kidney function), and measured
357 Alanine Aminotransferase/ALT enzyme levels (liver function), in *Myo1c*-KO mice ($n=4$
358 mice per individual functional analysis) and compared these values to their WT littermates
359 ($n=4$ mice per individual functional analysis). All of these analyses showed no pathological
360 defects in systemic organs of *Myo1c*-KO animals when compared to the age-matched
361 WT littermates (**Figs. S7a'-c'** and **S8**). Overall, these results indicate that except for the
362 retinal phenotypes, *Myo1c*-KO animals retained normal physiology of the systemic organs
363 examined.

364

365 Discussion

366 The trafficking of the G-protein coupled receptor (GPCR) Type II Opsins from the
367 photoreceptor IS to the OS represents a critical event in the initiation of phototransduction
368 for visual function in vertebrates. Our work identified for the first time an unconventional
369 motor protein, MYO1C, as a novel trafficking regulator of both rod and cone opsins to the
370 photoreceptor OS in mice. In this study, based on MYO1C localization within the IS and
371 OS of photoreceptors, and using a whole-body *Myo1c*-KO mouse model, we functionally
372 identified MYO1C as a novel component of retinal physiology and was specifically found
373 to be involved in photoreceptor cell function. Retinal analysis of *Myo1c*-KO mice identified
374 opsins as novel cargo for MYO1C. In the absence of MYO1C, both young and adult
375 *Myo1c*-KO mice showed impaired opsin trafficking, where rhodopsin was retained in the
376 photoreceptor IS and the cell bodies. **In contrast, cone opsins showed no retention in the**
377 **cell body or mistrafficking to other retinal cell layers, although staining patterns revealed**
378 **deformed cone OS shapes.** These two phenotypes manifested as a progressive decline
379 of visual responses in the rod ERGs and shorter photoreceptor OS lengths as *Myo1c*-KO
380 animals aged, indicating a progressive retinal phenotype. **Interestingly, trafficking of other**
381 **OS proteins (CNGA1, arrestin, and transducin) were largely unaffected in the absence of**
382 **MYO1C. The genetic deletion of *Myo1c* only affected retina, and the other systemic**
383 **organs examined, including heart, liver, and kidney, remained unaffected. Use of PCIP**
384 **as an allosteric inhibitor of MYO1C ATPase and motor activity resulted in retinal**
385 **phenotypes similar to those observed in *Myo1c*-KO mice and thus confirmed that MYO1C**
386 **plays a critical role in the trafficking of opsin to the photoreceptor OS.** Overall, our data
387 points to a novel mechanism by which MYO1C regulates opsin trafficking from the

388 photoreceptor IS to OS, a critical event for photoreceptor function and long-term
389 photoreceptor cell homeostasis. Our study identifies an unconventional motor protein
390 MYO1C as an essential component of mammalian photoreceptors, **where it plays a**
391 **canonical** role in promoting opsin trafficking and maintaining normal visual function.

392

393 **MYO1C and Other Opsin Trafficking Proteins:** *Myo1c*-KO mice exhibited rhodopsin
394 mislocalization similar to that of *Rpgr*^{-/-}, *Myo7a*^{Sh1}, *Rp1*^{-/-}, *Kinesin II*^{-/-}, and *Tulp1*^{-/-}
395 mutant mice [1-9]. Since MYO1C primarily localized to photoreceptor IS and OS, is known
396 to be involved in protein trafficking, and uses actin as a track [14, 23], we hypothesized
397 that MYO1C participates in the movement of opsins from IS to the OS of photoreceptors.
398 This hypothesis was supported by the observation that the rod opsins were mislocalized
399 to IS and cell bodies. Defective assembly of cone OS in *Myo1c*-KO mice suggests that
400 this phenotype is caused by an aberrant protein transport with OS degeneration as a
401 secondary event. The normal ultrastructure of photoreceptors in our *Myo1c*-KO mice
402 suggests that the retinal abnormalities in these animals were not due to structural defects
403 in photoreceptors per se, but instead were induced by aberrant motor function leading to
404 opsin mislocalization.

405

406 **MYO1C Contributed to Phototransduction and Retinal Homeostasis:** The opsin
407 molecules and other phototransduction proteins are synthesized in the cell body of the
408 photoreceptor [42, 43]. They are then transported to the distal IS [44] and subsequently
409 to the OS. Little is known about these transport processes and the molecular components
410 involved in this process [1-9]. The localization of MYO1C in the rod photoreceptors' IS

411 and OS, and in cone OS, suggested that opsins may utilize this molecular motor for
412 transport to the OS. The immunohistochemical analysis of *Myo1c*-KO animals indicated
413 that while rod and cone opsins trafficked to the OS, significant mislocalization was noted
414 for rhodopsin in the IS and cell bodies in the ONL (**Fig. 2**). Since they represent plasma
415 membrane structural proteins, cone opsins presumably contribute to the cone OS stability
416 and rhodopsin to the rod OS formation and stability [7]. Hence, photoreceptor OS
417 shortening/degeneration in *Myo1c*-KO mice may be attributed, in large part, to the
418 mistrafficking of opsins to the IS or a progressive reduction of opsins in the OS membrane.
419 Notably, the pattern of opsin mislocalization observed in *Myo1c*-KO mice closely
420 resembled the retinal phenotype observed in our previously reported *Tulp1*-KO mice [4,
421 45], *Cnga3*^{-/-} mice [5], *Lrat*^{-/-} and *Rpe65*^{-/-} mice [3, 8, 9], GC1-KO mice [1, 6], and, to
422 some extent in CFH (complement factor H)-KO animals [2]. Importantly, in all these
423 studies, photoreceptor OS were unstable, and significant degeneration was noted.
424 However, because 85-90% of OS protein is rhodopsin, the mislocalization of other less
425 abundant proteins cannot be ruled out in the photoreceptors of *Myo1c*-KO mice.

426

427 **Contributions from Other Motor proteins in Opsin trafficking:** Although this study
428 demonstrates mistrafficking of opsins due to a loss of MYO1C, the majority of opsin was
429 still correctly localized, suggesting that contribution or compensation from other myosins
430 cannot be ruled out. Nevertheless, the contributions from MYO1C were highly significant
431 as its genetic deletion showed specific physiological defects in mouse retinas. It is likely
432 that some redundancy exists among molecular motors, and several known candidates
433 might compensate for the lack of MYO1C in photoreceptor function. However, the qPCR

434 analysis of the retinas from WT and *Myo1c*-KO mice did not suggest compensation from
435 other family myosin 1 members (**Fig. S9**). Interestingly, the upregulation of *Myo1f* in our
436 study was unable to rescue the *Myo1c* retinal phenotype suggesting that *Myo1f* is unable
437 to compensate for the functional loss of *Myo1c* in retina (**Fig. S9**). However,
438 compensation by other motor proteins, including the members of kinesin superfamily [46,
439 47], myosin VIIa, and conventional myosin (myosin II) [48, 49], which have also been
440 detected in the RPE and retina, cannot be ruled out and need further investigation.
441 Overall, these results support a direct role for MYO1C in opsin trafficking in the
442 photoreceptor cells of the retina and provide evidence that defective protein transport
443 pathways are a pathologic mechanism responsible for OS degeneration and decreased
444 visual function in these mice.

445

446 **Methods**

447 **Materials:** All chemicals, unless stated otherwise, were purchased from Sigma-Aldrich
448 (St. Louis, MO, USA) and were of molecular or cell culture grade quality.

449

450 ***Myo1c*-knockout (*Myo1c*-KO) Mouse Model:** Mice were kept with *ad libitum* access to
451 food and water at 24°C in a 12:12 h light–dark cycle. All mice experiments were approved
452 by the Institutional Animal Care and Use Committee (IACUC protocol #00780; G.P.L.) of
453 the Medical University of South Carolina, and performed in compliance with ARVO
454 Statement for the use of Animals in Ophthalmic and Vision Research. We have previously
455 generated *Myo1c* transgenic mice (*Myo1c^{fl/fl}*) in C57BL/6N-derived embryonic stem

456 cells, flanking exons 5 to 13 of the mouse *Myo1c* gene, which has allowed us to
457 specifically delete all *Myo1c* isoforms in a cell-specific manner [29]. Here a complete
458 *Myo1c*-knockout was generated by crossing *Myo1c^{fl/fl}* mice with an **F-actin Cre mouse**
459 **strain (B6N.FVB-Tmem163Tg(ACTB-cre)2Mrt/CjDswJ)** obtained from Jackson Labs. We
460 will refer to the *Myo1c^{fl/fl}* x f-actin Cre cross as *Myo1c* knockout (*Myo1c*-KO) mice. For
461 this study, the *Myo1c*-KO mice were crossed onto a C57BL/6J background to avoid
462 potential problems with the *Rd8* mutation (found in C57BL/6N lines) [50]. **Equal numbers**
463 **of male and female mice (50:50 ratio) were used per group and time-point.**

464

465 **Immunohistochemistry and Fluorescence Imaging:** **Light-adapted mice were**
466 **ethanized and eyes immediately enucleated.** Eyes were fixed in 4% paraformaldehyde
467 buffered with 1X PBS for 2 hours at 4°C using established protocols [58]. After fixation,
468 samples were washed in 1X PBS and embedded in paraffin and processed (MUSC
469 Histology core facility). Sections (10 µm) were cut and transferred onto frost-free slides.
470 Slide edges were lined with a hydrophobic marker (PAP pen) and deparaffinized using
471 xylene and processed through ethanol washes before blocking for 1-2 hours at RT.
472 Blocking solution (1% BSA, 5% normal goat serum, 0.2% Triton-X-100, 0.1% Tween-20
473 in 1X PBS) was applied for 2 hours in a humidified chamber. Primary antibodies were
474 diluted in blocking solution as follows: anti-rhodopsin (1:500, Abcam, 1D4), anti-Myo1c
475 (1:100), cone-arrestin (1:250, Millipore-Sigma, St. Louis, MO), conjugated PNA-488
476 (1:2000, Molecular Probes, Eugene, OR), anti-red/green cone opsin (M-opsin; 1:500;
477 Millipore, St. Louis, MO), anti S-opsin (1:500, Millipore/Sigma, St. Louis, MO), ZO1
478 (1:2000, Invitrogen), Pde6b (1:300, ThermoFisher), **CNGA1 (1:250, Abcam), rod arrestin**

479 (1:250, Invitrogen), Stra6 (1:250, Millipore-Sigma), CRALBP (1:100, Invitrogen), rod
480 transducin (1:250, Santa Cruz), and 4',6-diamidino-2-phenylendole (DAPI; 1:5000,
481 Invitrogen) or Hoechst (1:10,000, Invitrogen) was used to label nuclei. All secondary
482 antibodies (Alexa 488 or Alexa 594) were used at 1:5000 concentrations (Molecular
483 Probes, Eugene, OR). Optical sections were obtained with a Leica SP8 confocal
484 microscope (Leica, Germany) and processed with the Leica Viewer software. All
485 fluorescently labeled retinal sections on slides were analyzed by the BioQuant NOVA
486 Prime Software (R & M Biometrics, Nashville) and fluorescence within individual retinal
487 layers quantified using Image J or Fiji (NIH).

488

489 **Measurement of Photoreceptor ONL thickness and OS lengths:** The lengths of the
490 photoreceptor OS in WT and *Myo1c*-KO animals (from H&E sections of retinas) were
491 imaged (Keyence BZ-X800 microscope) and measured at 12 consecutive points (at 150
492 μm distances) from the optic nerve (ON). The OS length was measured from the base of
493 the OS to the inner side of the retinal pigment epithelium. The total number of layers of
494 nuclei in the ONL of retinal sections through the optic nerve (ON) was imaged (Keyence
495 BZ-X800 microscope) and measured at 12 locations around the retina, six each in the
496 superior and inferior hemispheres, starting at 150 μm from the ON. Retinal sections ($n=$
497 5-7 retinal sections per eye) from $n=8$ mice for each genotype and time-point were
498 analyzed. Two-way ANOVA with Bonferroni post-tests compared *Myo1c*-KO to WT mice,
499 at each segment measured.

500

501 **PCIP (Pentachloropseudilin) retro-orbital injections**

502 We and others have previously shown that the natural compound pentachloropseudilin
503 (PCIP) acts as an allosteric inhibitor of MYO1C ATPase and motor activity [38-41, 51-53].
504 To test whether the inhibition of MYO1C function by PCIP affects opsin trafficking, PCIP
505 was retro-orbitally injected (5mg/kg body weight) into the right eye of two-month old WT
506 animals ($n=2$). At this concentration, PCIP was observed to inhibit all *Myo1c* isoforms
507 without affecting non-*Myo1* Myosins [35, 38, 40, 41, 51-56]. The control set of WT animals
508 ($n=2$) received retro-orbital injections of vehicle control (DMSO). Post 7-8 hours injection,
509 mice were euthanized, both eyes were harvested, and fixed in 4% PFA for histological
510 analysis.

511
512 **ERG Analysis:** Dark-adapted WT and *Myo1c*-KO mice (50:50 ratio of male and female;
513 $n=8$ each genotype) at 2 month of age (young mice; early time-point), and 6 month of age
514 (end time-point) were anesthetized by intraperitoneal injection of a ketamine/xylene
515 anesthetic cocktail (100 mg/kg and 20 mg/kg, respectively) and their pupils were dilated
516 with 1% tropicamide and 2.5% phenylephrine HCl. ERGs were performed under dim red-
517 light in the ERG rooms in morning (8am-12noon). Scotopic ERGs were recorded with a
518 computerized system (UTASE-3000; LKC Technologies, Inc., Gaithersburg, MD, USA),
519 as previously described [57-59].

520
521 **TEM analysis of retinas:** Eyecups at the indicated time-points were harvested and fixed
522 overnight at 4°C in a solution containing 2% paraformaldehyde/2.5% glutaraldehyde
523 (buffered in 0.1M cacodylate buffer). Samples were rinsed in the buffer (0.1 M cacodylate
524 buffer). Post-fixative 2% OsO₄/0.2 M cacodylate buffer 1 hour at 4°C, followed by 0.1 M

525 cacodylate buffer wash. The samples were dehydrated through a graded ethanol series
526 and then embedded in epon (EMbed 812; EM Sciences). For TEM analysis, each eye
527 ($n=6$ individual eyes from $n=6$ animals of each genotype) was cut in half before
528 embedding in epon blocks. Sections were parallel to the dorsoventral meridian and near
529 the optic nerve (ON). The cured blocks were sectioned at 0.5 microns (semi-thin plastic
530 sections) and stained with 1% toluidine blue to orient the blocks to the required specific
531 cell types. The blocks were trimmed to the precise size needed for ultrathin sectioning.
532 The blocks were cut at 70 nm and gathered on 1-micron grids. The grids were air-dried,
533 stained with uranyl acetate for 15 minutes, lead citrate for 5 minutes, and rinsed between
534 each stain. They were allowed to dry and imaged with a JEOL 1010. Images were
535 acquired with a Hamamatsu camera and software. All samples were processed by the
536 Electron Microscopy Resource Laboratory at the Medical University of South Carolina, as
537 previously described [57].

538

539 **Western Blot Analysis and Densitometry:** Total protein from cells or mouse tissues
540 ($n=3$ per genotype) were extracted using the M-PER protein lysis buffer
541 (ThermoScientific, Beverly, MA) containing protease inhibitors (Roche, Indianapolis, IN).
542 Approximately 25 μ g of total protein was electrophoresed on 4-12% SDS-PAGE gels and
543 transferred to PVDF membranes. Membranes were probed with primary antibodies
544 against anti-Myo1c (1:250), CRALBP (1:100, Invitrogen), Rod transducin (1:250, Santa
545 Cruz), PKC α (1:500, Novus Biologicals), and β -Actin or Gapdh (1:10,000, Sigma) in
546 antibody buffer (0.2% Triton X-100, 2% BSA, 1X PBS) [54,55,70]. HRP conjugated
547 secondary antibodies (BioRad, Hercules, CA) were used at 1:10,000 dilution. Protein

548 expression was detected using a LI-COR Odyssey system, and relative intensities of each
549 band were quantified (densitometry) using Image *J* software version 1.49 and normalized
550 to their respective loading controls. **Each western blot analysis was repeated thrice.**

551

552 **Co-immunoprecipitation (co-IP) Assays:** Co-immunoprecipitation of endogenously
553 expressed proteins (MYO1C and rhodopsin) was performed using mouse retinal extracts.
554 Six retinas of each genotype ($n=3$ animals of WT and *Myo1c*-KO) were used for extraction
555 of retinal proteins in 250 μ L of RIPA buffer (phosphate-buffered saline [PBS] containing
556 0.1% sodium dodecyl sulfate [SDS], 1% Nonidet P-40, 0.5% sodium deoxycholate, and
557 100 mM potassium iodide) with EDTA-free proteinase inhibitor mixture (Roche Molecular
558 Biochemicals). Lysates were cleared by centrifugation at 10000 rpm for 10 min at 4°C.
559 The prepared lysates were further incubated with anti-Myo1c, anti-rhodopsin, and
560 mouse/rabbit IgG overnight at 4°C and further with protein G-coupled agarose beads
561 (ROCHE) for 1-2 h. Beads were then collected by centrifugation at 3000 rpm for 5 min at
562 4°C, extensively washed in 1X PBS, and resuspended in SDS gel loading buffer. The
563 proteins were separated on a 10% SDS-PAGE, transferred to a PVDF membrane, and
564 analyzed by immunoblotting with the corresponding antibodies (**Fig. S6**).

565

566 **Overlay direct binding assay:** Rhodopsin protein was expressed in HEK293 cells using
567 transient transfection (pcDNA3 rod opsin construct, a gift from Robert Lucas (Addgene
568 plasmid # 109361, <http://n2t.net/addgene:109361>; RRID:Addgene_109361) [57] and
569 immunoprecipitated from the cell lysates using an anti-rhodopsin antibody (Abcam). In
570 parallel, rhodopsin was similarly immunoprecipitated from the mouse retinal lysate. The

571 immunoprecipitated complexes were separated on SDS-PAGE gel and transferred to
572 PVDF membrane. The membrane was then probed by overlaying it with 5 µg of
573 baculovirus-produced and purified recombinant full-length MYO1C FL or GFP-MYO1C-
574 790-1028 (tail domain, also known as the cargo domain [13]) protein, by incubating at 4°C
575 for 4 h. Following incubation, the membranes were western blotted with MYO1C antibody
576 to detect the direct binding of MYO1C to the rhodopsin bands. **The location of rhodopsin**
577 **on the membranes was marked by separately probing these membranes with an anti-**
578 **rhodopsin (1:500, Millipore Sigma) antibody (Fig. S6).**

579
580 **Quantitative Real Time-PCR:** RNA was isolated from retinas of WT and *Myo1c*-KO
581 animals using Trizol reagent, and processed as described previously [55,70]. One
582 microgram of total RNA was reverse transcribed using the SuperScript II cDNA Synthesis
583 Kit (Invitrogen, Eugene, OR). Quantitative Real-Time PCR (qRT-PCR) was carried out
584 using SYBR green 1 chemistry (BioRad, Hercules, CA). Samples for qRT-PCR
585 experiments were assayed in triplicate using the BioRad CFX96 Q-PCR machine. Each
586 experiment was repeated twice ($n=6$ reactions for each gene), using newly synthesized
587 cDNA.

588
589 **Liver function tests using Alanine Aminotransferase (ALT) assays:** To extract total
590 protein, liver tissue from WT or *Myo1c*-KO mice (pooled livers $n=4$ mice per genotype
591 respectively) were homogenized in RIPA buffer on ice and then centrifuged at 14,000 rpm
592 at 4°C for 10 min. Supernatant was collected, and the protein concentration was
593 estimated using the Bio-Rad Protein Assay Dye Reagent (Sigma). 10 µl of liver lysate

594 was transferred to 96-well plate and ALT was measured using a microplate-based ALT
595 activity assay kit (Pointe Scientific, Cat. A7526). Five biological replicates were used in
596 the assay.

597

598 **Heart function tests using Echocardiographic (ECHO) analyses:** Echocardiographic
599 (ECHO) analysis was performed on adult wildtype (WT) and *Myo1c*-KO animals ($n=4$ per
600 genotype) at the MUSC Cardiology Core Facility. For ECHO experiments, mutant and
601 wild-type littermate controls were anesthetized in an induction chamber with 5%
602 isoflurane in 100% oxygen. They were removed and placed on a warming table where
603 anesthesia was maintained via nose cone delivery of isoflurane (1% in 100% oxygen).
604 They were placed in the supine position, and the thoracic area was shaved. The limbs
605 were taped to the platform to restrict animal movement during echocardiography
606 acquisition. This also provided a connection to ECG leads embedded in the platform.
607 Sonography gel was applied to the chest and echocardiographic measurements of the
608 peristernal long axis and short axis of the heart were acquired to derive the systolic and
609 diastolic parameters of heart function. ECHO measurements were estimated using vevo
610 2100 instrumentation.

611

612 **Statistical Analysis:** Data were expressed as means \pm standard deviation by ANOVA in
613 the Statistica 12 software (StatSoft Inc., Tulsa, Oklahoma, USA). Differences between
614 means were assessed by Tukey's honestly significant difference (HSD) test. P -values
615 below 0.05 ($P<0.05$) were considered statistically significant. For western blot analysis,
616 relative intensities of each band were quantified (densitometry) using the Image J

617 software version 1.49 and normalized to the loading control β -actin. The qRT-PCR
618 analysis was normalized to 18S RNA, and the $\Delta\Delta C_t$ method was employed to calculate
619 fold changes. Data of qRT-PCR were expressed as mean \pm standard error of mean
620 (SEM). Statistical analysis was carried out using PRISM 8 software-GraphPad.

621

622 **Data Availability**

623 The authors declare that all data supporting the finding of this study are available within
624 this article and its supplementary information files or from the lead corresponding author
625 (G.P.L) upon request. The plasmids will be available from the lead corresponding author
626 (G.P.L) upon request.

627

628 **Disclosure**

629 All the authors declared no competing interests.

630

631 **Acknowledgements**

632 This work was supported by the National Institute of Health (NIH) grants, R21EY025034
633 and R01EY030889 to G.P.L.; 2R01DK087956-06A1, R56-DK116887-01A1, and
634 1R03TR003038-01 to D.N.; **EY027013-02 to M.R.B.; and R01EY027355 to S.H.** This
635 project was also supported in part by a DCI research grant (019898-001) and by a SCTR-
636 NIH/NCATS grant (5UL1TR001450) to G.P.L. The pCDNA3 Rod Opsin construct was a
637 gift from Dr. Robert Lucas (Addgene plasmid # 109361; <http://n2t.net/addgene:109361>;
638 RRID:Addgene_109361). **The authors thank George Robertson (Keyence Microscopes)**
639 **for the use of the Keyence BZ-X800 scope for semi-thin plastic sections, H&E sections,**

640 and immunofluorescence imaging. The authors thank Dr. Don Rockey (MUSC) and Dr.
641 Seok-Hyung Kim (MUSC) for recommending suitable liver function tests and/or for
642 providing the ALT liver function kit. We also thank Dr. Linda McLoon (University of
643 Minnesota) for critical review of the manuscript.

644

645 **Author Contributions**

646 G.P.L. and D.N. designed the research studies and wrote the manuscript. G.P.L., D.N.,
647 B. Rohrer, M.R.B., S.H., H-J. K., R.M., and J.S. edited the manuscript. G.P.L., A.K.S.,
648 M.R.B., R.D.M., E.O., D.N., E.A., B.R., S.W., S.H., and R.A.N. conducted experiments
649 and acquired data. A.K.S., G.P.L., M.R.B., S.W., S.H., J.S., R.D.M., R.A.N. and D.N.,
650 analyzed and interpreted the data. M.R.B. and S.H. performed ERG and interpreted the
651 data. R.D.M and R.A.N. performed ECHO and/or interpreted the data. R.M., H-J. K.,
652 R.A.N., R.D.M., M.R.B., J.S., S.H., B. Rohrer and J.H.L., supplied reagents, software, or
653 provided equipment for data analysis. All authors have read and agreed to the published
654 version of the manuscript.

655

656 **Figure Legends**

657 **Fig. 1: MYO1C localizes to photoreceptors in mouse retina:** Eyes from adult wild-type
658 (WT) and *Myo1c*-KO mice ($n=8$ mice per genotype; 50:50 ratio of male and female) were
659 harvested and retina sections ($n=5-7$ sections per eye) were immunostained with an anti-
660 MYO1C antibody (**a-c**), M-opsin antibody (**b, c**), followed by secondary (Alexa 488 or
661 Alexa 594) antibody staining. MYO1C (green fluorescence), M-Opsin (red fluorescence),
662 and DAPI or Hoechst (blue fluorescence). Figures in **a-c** are representative of retinal
663 sections ($n=5-7$ sections per eye) imaged from $n=8$ animals per genotype. (**b, c**) Merge

664 (orange) represents co-localization of MYO1C-488 (green) with M-Opsin-594 (red). RPE,
665 retinal pigmented epithelium; OS, outer segments; IS, inner segments; ONL, outer
666 nuclear layer. (a-c) Scale bar=50 μ m. (d) Total protein isolated from WT ($n=4$) and *Myo1c*-
667 KO ($n=4$) mouse retinas were pooled respectively and subjected to SDS-PAGE. Two
668 different concentrations of protein (10 μ g and 20 μ g) were used. Blots were then probed
669 with anti-Myo1c and Gapdh antibodies. Western blot analysis were repeated thrice.
670 Arrows indicate MYO1C protein band in retinal lysates of WT mice.

671
672 **Fig. 2: Genetic deletion of *Myo1c* in mice results in decreased visual function:** Dark-
673 adapted scotopic ERGs were recorded in response to increasing light intensities in
674 cohorts of control wild-type/WT (blue bars, blue-traces) and *Myo1c*-KO (red bars, red-
675 traces) mice of two month old (a, c), and six month old (b, d). Two-month-old *Myo1c*-KO
676 mice had lower dark-adapted *a*- and *b*-wave amplitudes compared with controls (post-
677 hoc ANOVA: *a*-waves, * $p<0.0068$; *b*-waves, $p<0.0098$, n.s. not significant.), in particular
678 at higher light intensities (-40, -30, -20, -10, 0 dB). Six-month-old *Myo1c*-knockout mice
679 had lower dark-adapted *a*- and *b*-wave amplitudes compared with controls (post-hoc
680 ANOVA: *a*-waves, ** $p<0.005$; *b*-waves, ** $p<0.005$), in particular at higher light intensities
681 (-40, -30, -20, -10, 0 dB). Photoreceptor cell responses (*a*-waves), which drive the *b*-
682 waves, were equally affected in 6-months old *Myo1c*-KO animals (both reduced on
683 average between 38-45% of WT animals). Data are expressed as mean \pm S.E. (*Myo1c*-
684 KO mice and WT mice, $n=8$ per genotype and age-group; 50:50 ratio of male and female).
685

686 **Fig. 3: Immunohistochemical analysis of wild-type/WT and *Myo1c*-knockout mice**
687 **retinas shows opsin trafficking defects: (a)** Levels and localization of rhodopsin (Rho);
688 **b**, red/green medium wavelength cone opsin (M-opsin); **c**, short wavelength cone opsin
689 (S-opsin); **d**, PNA-488, were analyzed in two and six-months old WT and *Myo1c*-KO mice
690 retinas. Arrows in panel **a** highlight rhodopsin mislocalization to IS and cell bodies in
691 *Myo1c*-knockout mouse retinas. Images in panels **a-d** are representative of
692 immunostained retinal sections ($n=5-7$ sections per eye) imaged from $n=8$ animals per
693 genotype and age-group (50:50 ratio of male and female). Scale bar=75 μm (**a**); Scale
694 bar=50 μm (**b, c, d**). OS, outer segments; IS, inner segments; ONL, outer nuclear layer;
695 INL, inner nuclear layer; OPL, outer plexiform layer.

696
697 **Fig. 4: Immunohistochemical analysis of protein trafficking in photoreceptors of**
698 **wild-type/WT and *Myo1c*-knockout mice retinas:** Levels and localization of (a) cone
699 arrestin (ARR), (b) Pde6b; (c) CNGA1; (d) Rod Arrestin (ARR1); and (e) G-protein
700 (Transducin), were analyzed in WT and *Myo1c*-KO mice retinas to evaluate protein
701 trafficking to photoreceptor OS. Red Arrows in **panel a** highlight cone photoreceptor
702 nuclei and OS in WT mouse retinas that were significantly reduced or shorter respectively
703 in *Myo1c*-KO animals (white arrows in **a**). Images in panels **a-e** are representative of
704 immunostained retinal sections ($n=5-7$ sections per eye) imaged from $n=8$ animals per
705 genotype and age group (50:50 ratio of male and female). **Panels a, b**, mice were 2-3
706 months of age. **Panels c-e**, mice were 3-4 months of age. (f) protein distribution (in %) of
707 CNGA1, Rod ARR1, and Transducin, within the photoreceptor OS and IS, in light adapted
708 mice. For quantification of protein distribution within retinal layers, 5-7 retinal sections

709 from each eye ($n=8$ animals for each genotype) were analyzed using Image J. (g)
710 Representative western blot ($n=3$ repeats) images of retinal proteins from 3-4 month old
711 WT and *Myo1c-KO* mice ($n=2$ animals per genotype) showed no significant differences
712 in protein expression of key retinal genes among genotypes. OS, outer segments; IS,
713 inner segments; ONL, outer nuclear layer; INL, inner nuclear layer; OPL, outer plexiform
714 layer; IPL, inner plexiform layer.

715

716 **Fig. 5: Histological analysis shows reduced photoreceptor OS lengths in *Myo1c-***
717 **KO mice retinas: (a, b)** Retinas from 2 and 6 month old WT and *Myo1c-KO* mice were
718 sectioned using an ultra-microtome and semi-thin plastic sections were obtained to
719 evaluate pathological consequences of MYO1C loss. Quantification of OS lengths from
720 H&E sections (c, two month old mice; d, 6 month old mice) and ONL thickness (e, two
721 month old mice; f, six months old mice) using “spider graph” morphometry. The OS
722 lengths and total number of layers of nuclei in the ONL of from H&E sections through the
723 optic nerve (ON; 0 μm distance from Optic Nerve and starting point) was measured at 12
724 locations around the retina, six each in the superior and inferior hemispheres, each
725 equally at 150 μm distances. RPE, retinal pigmented epithelium; OS, outer segments; IS,
726 inner segments; ONL, outer nuclear layer; INL, inner nuclear layer; OPL, outer plexiform
727 layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Retinal sections ($n=5-7$ sections
728 per eye) from $n=8$ mice each genotype and time-point (50:50 ratio of male and female)
729 were analyzed. Two-way ANOVA with Bonferroni posttests compared *Myo1c-KO* mice
730 with WT in all segments. ** $p<0.005$, for OS length in only 6 month old *Myo1c-KO* mice

731 compared to WT mice; and n.s. (not significant) for ONL thickness in both 2 month and 6
732 month old *Myo1c*-KO animals, compared to WT mice). (a, b) Scale bar=100 μ m.

733

734 **Fig. 6: Ultrastructural analysis of rods and cone photoreceptors using**
735 **transmission electron microscopy (TEM):** Representative TEM images of rod
736 photoreceptors from two month (a) and six month (b) old WT and *Myo1c*-KO mice, are
737 presented. Representative images of cone photoreceptors from 2 month old WT (c) and
738 *Myo1c*-KO (d) mice. (a) Scale bar=2 μ m (b) Scale bar=600 nm (c, d) Scale bar=400 nm.

739 Data is representative of $n=6$ retinal sections per eye from $n=8$ mice per genotype and
740 time-point. (e) Rod OS (ROS) length in WT animals were measured and compared to
741 *Myo1c*-KO animals. (f) Cone OS (COS) length in WT animals were measured and
742 compared to *Myo1c*-KO animals. * $p<0.05$; ** $p<0.005$. RPE, retinal pigmented epithelium.

743

744 **Fig. 7: Histological and immunohistochemical analysis of mice injected with PCIP:**
745 The *Myo1c* specific inhibitor PCIP (pentachloropseudilin) or vehicle control DMSO was
746 injected retro-orbitally into the right eye of WT animals ($n=2$ per treatment). (a) Levels and
747 localization of rhodopsin (Rho) and (b), red/green opsins (M-opsin). (c) Semi-thin plastic
748 sections of retina from mice were obtained to evaluate pathological consequences of
749 PCIP treatment. (d) Quantification of ONL thickness and (e) photoreceptor OS lengths
750 using “spider graph” morphometry, from H&E sections. The OS length and total number
751 of layers of nuclei in the ONL of semi-thin plastic sections through the optic nerve (ON;
752 0 μ m distance and the starting point) was measure at 12 locations around the retina, six
753 each in the superior and inferior hemispheres, each equally at 150 μ m distance. Retinal

754 sections ($n=10-12$ sections per eye) from $n=2$ mice of each treatment group were
755 evaluated for ONL thickness and OS lengths. (a, b) Scale bar=50 μ m (c) Scale bar=100
756 μ m. RPE, retinal pigmented epithelium; OS, outer segments; IS, inner segments; ONL,
757 outer nuclear layer; INL, inner nuclear layer; OPL, outer plexiform layer.

758

759 **Fig. 8: Rhodopsin is a direct cargo for MYO1C:** (a) Mice retinal protein lysates were
760 isolated from *Myo1c*-KO and wild type (WT) mice (6 retinas pooled from $n=3$ mice per
761 genotype) and subjected to co-immunoprecipitation analysis. Rhodopsin was co-
762 immunoprecipitated with MYO1C antibody (top panel). In a reciprocal manner, MYO1C
763 was co-immunoprecipitated with Rhodopsin antibody (bottom panel). (b) Using Rhodopsin
764 antibody, Rhodopsin (RHO) was immunoprecipitated either from mice retinal lysates or
765 from HEK293 cells (transfected with pCDNA rhodopsin plasmid) where Rhodopsin was
766 overexpressed. The immunoprecipated Rhodopsin was separated using SDS-PAGE and
767 transferred to nitrocellulose membranes. The rhodopsin bound to nitrocellulose
768 membrane was then incubated with 5ug of purified recombinant active MYO1C-full length
769 (b) or MYO1C C-terminal cargo domain protein (c) generated from a baculovirus
770 expression system. To analyze if MYO1C binds to immobilized Rhodopsin, blots were
771 washed and western blotted with MYO1C antibody. A positive signal with MYO1C showed
772 direct binding of MYO1C to various Rhodopsin multimers (arrows) present in the retinal
773 lysate and overexpressed pCDNA3-Rhodopsin in HEK293 cells.

774

775 **Supplementary Figures**

776

777 **Fig. S1: *Myo1c* targeting construct and Western blot analysis of MYO1C in systemic**
778 **tissues:** (a) Schematic representation of the *Myo1c* targeting construct for generation of
779 the *Myo1c*-KO mouse line. (b) Western blot analysis confirmed MYO1C absence in
780 various systemic tissues of *Myo1c*-KO mice. Absence of MYO1C did not affect MYO1B
781 or MYO1E expression. Actin was used as the protein loading control. Representative
782 images from multiple western blots ($n=3$) from $n=3$ animals per genotype.

783

784 **Fig. S2: MYO1C expression in mouse tissue by immunofluorescence:** Expression of
785 MYO1C and ZO1 in systemic tissues, kidney (a), liver (b), and heart (c) of WT and *Myo1c*-
786 KO animals ($n=3$ per genotype) by immunofluorescence. WT, wild type; KO, knockout.
787 Representative images from $n=3$ animals. (a, c) Scale bar=50 μm ; (b) Scale bar=75 μm

788

789 **Fig. S3: Quantification of OS lengths and distribution of Opsins in retinas of *Myo1c*-**
790 **knockout mice from Figure 3:** Rhodopsin distribution within rod OS, IS, and ONL were
791 quantified in two month old animals (a, b, and c, respectively) and in six month old animals
792 (d, e, and f, respectively). For quantification of rhodopsin distribution, 5-7 retinal sections
793 from each eye ($n=8$ animals for each genotype and time-point) were analyzed using
794 Image J or FIJI software. Mann-Whitney *U* test was used for statistical analysis and
795 represented in Box-Whisker plots and considered significant * $p<0.05$; ** $p<0.005$.

796

797 **Fig. S4: Immunohistochemical analysis of protein in RPE of wild-type/WT and**
798 ***Myo1c*-knockout mice retinas:** The RPE specific protein STRA6 was used to evaluate
799 integrity of the RPE in both WT and *Myo1c*-KO mice. Representative images from $n=8$

800 animals (5-7 sections per eye) per genotype and age. Scale bar=50 μ m. RPE, retinal
801 pigmented epithelium; ONL, outer nuclear layer; INL, inner nuclear layer.

802

803 **Fig. S5: Immunohistochemical and histological analysis of retinas from Cre+ mice:**

804 Retinal histology, H&E staining, and localization of rhodopsin (Rho), red/green cone opsin

805 (M-opsin) in WT (a) and Cre+ (b) mice. (a, b) Immunofluorescence Scale bar=50 μ m. (a,

806 b) Histology (H&E staining) Scale bar=100 μ m. Representative images from $n=3$ animals

807 each genotype at 2-3 months of age (5-7 retinal sections per eye). RPE, retinal pigmented

808 epithelium; OS, outer segments; IS, inner segments; ONL, outer nuclear layer; OPL, outer

809 plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell

810 layer.

811

812 **Fig. S6: Schematic representation of MYO1C-Rhodopsin Co-IP binding**

813 **experiments from figure 8:** Detailed flow chart of Co-IP binding experiments

814 representing figure 8 are shown.

815

816 **Fig. S7: Representative tissue histology and functional analysis of systemic organs**

817 **from WT and Myo1c-KO animals:** Systemic organs, liver (a), kidney (b), and heart (c),

818 of *Myo1c* and WT animals ($n=4$ each genotype at 3-4 months of age) were sectioned and

819 stained with haematoxylin & eosin (H&E) to evaluate for systemic pathology of whole-

820 body MYO1C loss. Functional analysis of systemic organs using ALT liver function tests

821 (a'), urine analysis for kidney proteinuria/albuminuria (b'), and heart function using

822 Echocardiography (c') was performed in *Myo1c*-KO animals and compared to WT

823 controls. **a'**, Liver function tests by Alanine Aminotransferase/ALT assay. No significant
824 change (n.s.) was found in total protein concentration or ALT activity of liver ($p>0.1$) in
825 *Myo1c*-KO compared to WT mice. Five biological replicates were used for each assay
826 and statistical test used was one-tailed students *t*-test. **b'**, approximately 20 μ l of urine
827 from *Myo1c*-KO and WT animals were electrophoresed on SDS-PAGE gels and stained
828 with Comassie blue. 5ug/ml BSA was used as positive control. BSA, bovine serum
829 albumin. **c'**, representative images from WT and *Myo1c*-KO heart showing B-Mode long
830 axis and M-Mode short axis. (**a, b, c**) Scale bar=50 μ m.

831
832 **Fig. S8: Detailed Echocardiographic (ECHO) parameters in WT and *Myo1c*-KO**
833 **animals:** Echocardiographic measurements was taken using the vevo 2100 ultrasound
834 imaging system, to access cardiac function among genotypes. (**a**) Left-ventricle at end-
835 diastole, Posterior wall thickness, and Septal wall thickness; (**b**) Left-ventricle (LV) Mass;
836 (**c**) Stroke volume (SV); (**d**) Left-ventricle ejection fraction (EF); (**e**) Left-ventricle end-
837 diastolic volume (EDV); and (**f**) tabular summary of ECHO values from $n=4$
838 animals/genotype at 3-4 months of age. By *t*-test, there were no statistically significant
839 differences between the two genotypes. Values presented as Mean \pm SEM.

840
841 **Fig. S9: qPCR analysis of various MYO1C family members in mice retina:** Retinas
842 from WT and *Myo1c*-KO mice were isolated and processed for qPCR analysis using
843 specific primers for various *Myo1c* family members including *Myo1b*, *d*, *e* and *f*. qPCR
844 analysis was performed in triplicates for each sample and repeated thrice with freshly
845 synthesized cDNA for each repeat experiment.

846 **References**

847

- 848 1. Baehr, W., et al., *The function of guanylate cyclase 1 and guanylate cyclase 2 in*
849 *rod and cone photoreceptors*. J Biol Chem, 2007. **282**(12): p. 8837-47.
- 850 2. Coffey, P.J., et al., *Complement factor H deficiency in aged mice causes retinal*
851 *abnormalities and visual dysfunction*. Proc Natl Acad Sci U S A, 2007. **104**(42): p.
852 16651-6.
- 853 3. Fan, J., et al., *Rpe65^{-/-} and Lrat^{-/-} mice: comparable models of leber congenital*
854 *amaurosis*. Invest Ophthalmol Vis Sci, 2008. **49**(6): p. 2384-9.
- 855 4. Grossman, G.H., et al., *Immunocytochemical evidence of Tulp1-dependent outer*
856 *segment protein transport pathways in photoreceptor cells*. Exp Eye Res, 2011.
857 **93**(5): p. 658-68.
- 858 5. Hüttl, S., et al., *Impaired channel targeting and retinal degeneration in mice lacking*
859 *the cyclic nucleotide-gated channel subunit CNGB1*. J Neurosci, 2005. **25**(1): p.
860 130-8.
- 861 6. Zhang, H., et al., *Trafficking of membrane-associated proteins to cone*
862 *photoreceptor outer segments requires the chromophore 11-cis-retinal*. J
863 Neurosci, 2008. **28**(15): p. 4008-14.
- 864 7. Pearing, J.N., et al., *Protein sorting, targeting and trafficking in photoreceptor*
865 *cells*. Prog Retin Eye Res, 2013. **36**: p. 24-51.
- 866 8. Zhang, T., et al., *Cone opsin determines the time course of cone photoreceptor*
867 *degeneration in Leber congenital amaurosis*. Proc Natl Acad Sci U S A, 2011.
868 **108**(21): p. 8879-84.
- 869 9. Karan, S., et al., *A model for transport of membrane-associated phototransduction*
870 *polypeptides in rod and cone photoreceptor inner segments*. Vision Research,
871 2008. **48**(3): p. 442-452.
- 872 10. Abdelkader, E., et al., *Severe retinal degeneration at an early age in Usher*
873 *syndrome type 1B associated with homozygous splice site mutations in MYO7A*
874 *gene*. Saudi J Ophthalmol, 2018. **32**(2): p. 119-125.
- 875 11. Cheng, L., et al., *Identification of a novel MYO7A mutation in Usher syndrome type*
876 *1*. Oncotarget, 2018. **9**(2): p. 2295-2303.
- 877 12. Arif, E., et al., *Motor protein Myo1c is a podocyte protein that facilitates the*
878 *transport of slit diaphragm protein Neph1 to the podocyte membrane*. Mol Cell Biol,
879 2011. **31**(10): p. 2134-50.
- 880 13. Nakamori, Y., et al., *Myosin motor Myo1c and its receptor NEMO/IKK-gamma*
881 *promote TNF-alpha-induced serine307 phosphorylation of IRS-1*. J Cell Biol, 2006.
882 **173**(5): p. 665-71.
- 883 14. Woolner, S. and W.M. Bement, *Unconventional myosins acting unconventionally*.
884 Trends Cell Biol, 2009. **19**(6): p. 245-52.
- 885 15. Bownds, D., *Site of attachment of retinal in rhodopsin*. Nature, 1967. **216**(5121):
886 p. 1178-81.
- 887 16. Palczewski, K., et al., *Crystal structure of rhodopsin: A G protein-coupled receptor*.
888 Science, 2000. **289**(5480): p. 739-45.
- 889 17. Wald, G., J. Durell, and C.C. St George, *The light reaction in the bleaching of*
890 *rhodopsin*. Science, 1950. **111**(2877): p. 179-81.

- 891 18. Wald, G. and R. Hubbard, *The Synthesis of Rhodopsin from Vitamin A(1)*. Proc
892 Natl Acad Sci U S A, 1950. **36**(2): p. 92-102.
- 893 19. Wang, J.K., J.H. McDowell, and P.A. Hargrave, *Site of attachment of 11-cis-retinal*
894 *in bovine rhodopsin*. Biochemistry, 1980. **19**(22): p. 5111-7.
- 895 20. Walsh, T., et al., *From flies' eyes to our ears: mutations in a human class III myosin*
896 *cause progressive nonsyndromic hearing loss DFNB30*. Proc Natl Acad Sci U S
897 A, 2002. **99**(11): p. 7518-23.
- 898 21. Rehman, A.U., et al., *Mutational Spectrum of MYO15A and the Molecular*
899 *Mechanisms of DFNB3 Human Deafness*. Human mutation, 2016. **37**(10): p. 991-
900 1003.
- 901 22. Samuels, I.S., et al., *Myosin 6 is required for iris development and normal function*
902 *of the outer retina*. Invest Ophthalmol Vis Sci, 2013. **54**(12):p. 7223-33.
- 903 23. Adamek, N., M.A. Geeves, and L.M. Coluccio, *Myo1c mutations associated with*
904 *hearing loss cause defects in the interaction with nucleotide and actin*. Cell Mol
905 Life Sci, 2011. **68**(1): p. 139-50.
- 906 24. Lin, T., et al., *A hearing loss-associated myo1c mutation (R156W) decreases the*
907 *myosin duty ratio and force sensitivity*. Biochemistry, 2011. **50**(11): p. 1831-8.
- 908 25. Skeie, J.M. and V.B. Mahajan, *Proteomic interactions in the mouse vitreous-retina*
909 *complex*. PLoS One, 2013. **8**(11): p. e82140.
- 910 26. Boguslavsky, S., et al., *Myo1c binding to submembrane actin mediates insulin-*
911 *induced tethering of GLUT4 vesicles*. Mol Biol Cell, 2012. **23**(20): p. 4065-78.
- 912 27. Bose, A., et al., *Unconventional myosin Myo1c promotes membrane fusion in a*
913 *regulated exocytic pathway*. Mol Cell Biol, 2004. **24**(12): p. 5447-58.
- 914 28. Fan, Y., et al., *Myo1c facilitates G-actin transport to the leading edge of migrating*
915 *endothelial cells*. J Cell Biol, 2012. **198**(1): p. 47-55.
- 916 29. Arif, E., et al., *The motor protein Myo1c regulates transforming growth factor-beta-*
917 *signaling and fibrosis in podocytes*. Kidney Int, 2019.
- 918 30. Crosson, C.E., et al., *Inhibition of histone deacetylase protects the retina from*
919 *ischemic injury*. Invest Ophthalmol Vis Sci, 2010. **51**(7): p. 3639-45.
- 920 31. Husain, S., D.E. Potter, and C.E. Crosson, *Opioid receptor-activation: retina*
921 *protected from ischemic injury*. Invest Ophthalmol Vis Sci, 2009. **50**(8): p. 3853-9.
- 922 32. Krebs, W. and H. Kühn, *Structure of isolated bovine rod outer segment*
923 *membranes*. Exp Eye Res, 1977. **25**(5): p. 511-26.
- 924 33. Pearing, J.N., et al., *Protein sorting, targeting and trafficking in photoreceptor*
925 *cells*. Progress in retinal and eye research, 2013. **36**: p. 24-51.
- 926 34. Calvert, P.D., et al., *Light-driven translocation of signaling proteins in vertebrate*
927 *photoreceptors*. Trends Cell Biol, 2006. **16**(11): p. 560-8.
- 928 35. Brandstaetter, H., et al., *Loss of functional MYO1C/myosin 1c, a motor protein*
929 *involved in lipid raft trafficking, disrupts autophagosome-lysosome fusion*.
930 Autophagy, 2014. **10**(12): p. 2310-23.
- 931 36. Mustafi, D., et al., *Photoreceptor phagocytosis is mediated by phosphoinositide*
932 *signaling*. FASEB journal : official publication of the Federation of American
933 Societies for Experimental Biology, 2013. **27**(11): p. 4585-4595.
- 934 37. Lopes, V.S., et al., *The Usher 1B protein, MYO7A, is required for normal*
935 *localization and function of the visual retinoid cycle enzyme, RPE65*. Human
936 molecular genetics, 2011. **20**(13): p. 2560-2570.

- 937 38. Chinthalapudi, K., et al., *Mechanism and specificity of pentachloropseudilin-*
938 *mediated inhibition of myosin motor activity.* J Biol Chem, 2011. **286**(34): p. 29700-
939 8.
- 940 39. Gupta, P., et al., *Myosin-1 inhibition by PCIP affects membrane shape, cortical*
941 *actin distribution and lipid droplet dynamics in early Zebrafish embryos.* PLoS One,
942 2017. **12**(7): p. e0180301.
- 943 40. Kittelberger, N., et al., *The role of myosin 1c and myosin 1b in surfactant*
944 *exocytosis.* J Cell Sci, 2016. **129**(8): p. 1685-96.
- 945 41. Martin, R., et al., *Total synthesis of pentabromo- and pentachloropseudilin, and*
946 *synthetic analogues--allosteric inhibitors of myosin ATPase.* Angew Chem Int Ed
947 Engl, 2009. **48**(43): p. 8042-6.
- 948 42. Young, R.W., *The renewal of photoreceptor cell outer segments.* J Cell Biol, 1967.
949 **33**(1): p. 61-72.
- 950 43. Young, R.W. and B. Droz, *The renewal of protein in retinal rods and cones.* J Cell
951 Biol, 1968. **39**(1): p. 169-84.
- 952 44. Findlay, J.B. and D.J. Pappin, *The opsin family of proteins.* Biochem J, 1986.
953 **238**(3): p. 625-42.
- 954 45. Lobo, G.P., et al., *Involvement of Endoplasmic Reticulum Stress in TULP1 Induced*
955 *Retinal Degeneration.* PLoS One, 2016. **11**(3): p. e0151806.
- 956 46. Beech, P.L., et al., *Localization of kinesin superfamily proteins to the connecting*
957 *cilium of fish photoreceptors.* J Cell Sci, 1996. **109 (Pt 4)**: p. 889-97.
- 958 47. Muresan, V., et al., *Evidence for kinesin-related proteins associated with the*
959 *axoneme of retinal photoreceptors.* Exp Eye Res, 1997. **64**(6): p. 895-903.
- 960 48. Chaitin, M.H. and N. Coelho, *Immunogold localization of myosin in the*
961 *photoreceptor cilium.* Invest Ophthalmol Vis Sci, 1992. **33**(11): p. 3103-8.
- 962 49. Williams, D.S., M.A. Hallett, and K. Arikawa, *Association of myosin with the*
963 *connecting cilium of rod photoreceptors.* J Cell Sci, 1992. **103 (Pt 1)**: p. 183-90.
- 964 50. Mattapallil, M.J., et al., *The Rd8 mutation of the Crb1 gene is present in vendor*
965 *lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced*
966 *mutant phenotypes.* Invest Ophthalmol Vis Sci, 2012. **53**(6): p. 2921-7.
- 967 51. Chung, C.L., et al., *Pentachloropseudilin Inhibits Transforming Growth Factor- β*
968 *(TGF- β) Activity by Accelerating Cell-Surface Type II TGF- β Receptor Turnover in*
969 *Target Cells.* Chembiochem, 2018. **19**(8): p. 851-864.
- 970 52. Iuliano, O., et al., *Myosin 1b promotes axon formation by regulating actin wave*
971 *propagation and growth cone dynamics.* Journal of Cell Biology, 2018. **217**(6): p.
972 2033-2046.
- 973 53. Cota Teixeira, S., et al., *Pentachloropseudilin Impairs Angiogenesis by Disrupting*
974 *the Actin Cytoskeleton, Integrin Trafficking and the Cell Cycle.* Chembiochem,
975 2019. **20**(18): p. 2390-2401.
- 976 54. Gupta, P., et al., *Myosin 1E localizes to actin polymerization sites in lamellipodia,*
977 *affecting actin dynamics and adhesion formation.* Biol Open, 2013. **2**(12): p. 1288-
978 99.
- 979 55. Rozbicki, E., et al., *Myosin-II-mediated cell shape changes and cell intercalation*
980 *contribute to primitive streak formation.* Nat Cell Biol, 2015. **17**(4): p. 397-408.
- 981 56. Prospéri, M.T., et al., *Myosin 1b functions as an effector of EphB signaling to*
982 *control cell repulsion.* J Cell Biol, 2015. **210**(2): p. 347-61.

- 983 57. Lobo, G.P., et al., *The exocyst is required for photoreceptor ciliogenesis and retinal*
984 *development*. J Biol Chem, 2017. **292**(36): p. 14814-14826.
985 58. Husain, S., *Delta Opioids: Neuroprotective Roles in Preclinical Studies*. J Ocul
986 Pharmacol Ther, 2018. **34**(1-2): p. 119-128.
987 59. Husain, S., et al., *PI3K/Akt Pathway: A Role in delta-Opioid Receptor-Mediated*
988 *RGC Neuroprotection*. Invest Ophthalmol Vis Sci, 2017. **58**(14): p. 6489-6499.
989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023


1024

1025

1026


1027

1028




1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055

1056
1057




1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081

1082
1083
1084
1085
1086
1087
1088
1089
1090




1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107

1108
1109
1110
1111
1112
1113



1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133

1134
1135
1136
1137
1138
1139
1140
1141
1142
1143



1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159

1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171





Figure 6


1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185

1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197




1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212

1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225




1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238

1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258




1259
1260
1261
1262
1263
1264

1265
1266
1267
1268




1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290

1291



1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313

Figure S4



1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339

1340
1341
1342






Figure S5

1343
1344
1345
1346
1347
1348
1349
1350
1351


Figure S6



1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365




1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376



1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387

Figure S9



1388